While further studies are needed to investigate MYO6 regulation of lymphoma cell dynamics and to design novel therapeutic approaches, a monoclonal antibody targeting the neoepitope generated by mutated CALR in myeloproliferative disorders has been generated. This evidence concerns the gene CALR and lymphoma.